newsfilter
← Latest News
GlobeNewswire·

Allarity Therapeutics Issues 2025 End of Year CEO Letter to Shareholders

TARPON SPRINGS, Fla., December 31, 2025 – Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a